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Mutations in the KV7.2 gene encoding for voltage-dependent K
+
channel subunits cause neonatal epilepsies with wide phenotypic
heterogeneity. Twomutations affecting the same positively charged
residue in the S4 domain of KV7.2 have been found in children af-
fected with benign familial neonatal seizures (R213W mutation) or
with neonatal epileptic encephalopathywith severe pharmacoresist-
ant seizures and neurocognitive delay, suppression-burst pattern at
EEG, and distinct neuroradiological features (R213Q mutation). To
examine the molecular basis for this strikingly different phenotype,
we studied the functional characteristics ofmutant channels by using
electrophysiological techniques, computational modeling, and ho-
mology modeling. Functional studies revealed that, in homomeric
or heteromeric conﬁgurationwith KV7.2 and/or KV7.3 subunits, both
mutations markedly destabilized the open state, causing a dramatic
decrease in channel voltage sensitivity. These functional changes
were (i) more pronounced for channels incorporating R213Q- than
R213W-carrying KV7.2 subunits; (ii) proportional to the number of
mutant subunits incorporated; and (iii) fully restored by the neuronal
Kv7 activator retigabine. Homology modeling conﬁrmed a critical
role for the R213 residue in stabilizing the activated voltage sensor
conﬁguration. Modeling experiments in CA1 hippocampal pyramidal
cells revealed that both mutations increased cell ﬁring frequency,
with the R213Q mutation prompting more dramatic functional
changes compared with the R213W mutation. These results suggest
that the clinical disease severity may be related to the extent of the
mutation-induced functionalK+ channel impairment, and set thepre-
clinical basis for the potential use of Kv7 openers as a targeted anti-
convulsant therapy to improve developmental outcome in neonates
with KV7.2 encephalopathy.
channelopathies | potassium channel gating | anticonvulsants | π-stacking
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Heteromeric assembly of KV7.2 (KCNQ2) and KV7.3(KCNQ3) voltage-dependent K+ channel subunits underlies
the M-current (IKM) (1), a slowly activating and deactivating K
+
neuronal current that regulates excitability in the subthreshold
range for action potential (AP) generation (2, 3) and is also in-
volved in network oscillation and synchronization control (4).
Mutations in KV7.2 (5, 6) and, more rarely, KV7.3 (7) genes
are responsible for benign familial neonatal seizures (BFNS),
a rare, autosomal-dominant epilepsy of newborns characterized
by recurrent seizures that begin in the very ﬁrst days of life in
otherwise healthy newborns and remit after a few weeks or
months; BFNS-affected individuals mostly display normal inter-
ictal EEG, neuroimaging ﬁndings, and psychomotor development.
More recently, KV7.2 mutations have been described in neo-
nates affected with pharmacoresistant seizures with psychomotor
retardation, suppression-burst pattern at EEG, and distinct
neuroradiological features, thus deﬁning a so-called “KV7.2 en-
cephalopathy” (8), as well as in children with Ohtahara syndrome
or early infantile epileptic encephalopathy with suppression-burst
(9), the most severe and the earliest developing age-related epi-
leptic encephalopathy (10).
In particular, two heterozygous mutations affecting the same
positively charged residue (R213) within the KV7.2 S4 trans-
membrane segment of the voltage-sensing domain (VSD) are as-
sociated with neonatal epileptic encephalopathy in a patient with
profound mental retardation, asymmetric spastic quadriplegia, and
macrocephaly (R213Q) (8, 11), or with typical BFNS (R213W) (12).
To investigate the molecular basis for such dramatically dif-
ferent phenotypes, we studied the biophysical characteristics of
channels incorporating KV7.2 R213Q/W mutant subunits in
homomeric and heteromeric conﬁguration with various ratios of
KV7.2 and/or KV7.3 subunits. The results obtained revealed that
both mutations decreased channel voltage sensitivity by reducing
the stability of the activated VSD conﬁguration; these gating
alterations appeared signiﬁcantly more pronounced for R213Q-
than R213W-incorporating channels, and were fully reversed by
the neuronal Kv7/IKM channel activator retigabine (13). Model-
ing experiments in hippocampal CA1 pyramidal cells whose
IKM incorporated the experimentally deﬁned mutation-induced
gating changes showed that R213W- and, more so, R213Q-
containing heteromeric channels markedly increased neuronal
excitability. Finally, analysis of the structural consequences of
R213W and R213Q substitutions in a homology-built model of
the activated conﬁguration of KV7.2 VSD suggested that, al-
though both mutations impeded the formation of ionized hy-
drogen bonds between R213 and neighboring negatively charged
amino acids, the introduction of a W, but not of a Q, residue at
R213 may provide a certain degree of VSD stabilization by creating
a unique aromatic staking interaction.
The present results reveal that the extent of mutation-induced
functional impairment may be related to the clinical severity of
the disease, thus uncovering genotype–phenotype correlations in
KV7.2-linked channelopathies that might have relevant impact on
disease-management procedures (i.e., for early genotyping), as well
as on clinical course prediction and pharmacological treatment.
Results
Functional Properties of Homomeric KV7.2 Channels Carrying R213W
(R6W) and R213Q (R6Q) Substitutions. Kv7 channels assemble as
tetramers, with each subunit displaying a core domain formed by
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six transmembrane segments (S1–S6), and cytoplasmic N-and
C-termini; within each subunit, the S1 to S4 segments form the
VSD arranged symmetrically around the pore. S4 shows a vari-
able number of positively charged amino acids (numbered from
0 to 7). Characteristic in all Kv7 subunits is the presence of an
uncharged Q residue (Q204 in KV7.2) at the position corre-
sponding to R3 in most Kv channels; R213 is the ﬁfth positively
charged residue along the KV7.2 S4 segment. To facilitate se-
quence comparison with other KV channels whose crystal struc-
tures have been determined and that carry a positive charge at R3,
the R213 residue in KV7.2 will be referred to as R6, and the
R213W and R213Q mutations as R6W and R6Q, respectively
(Fig. 1A), despite the fact that we previously used the R6 ab-
breviation for the adjacent R214 residue (11).
Homomeric KV7.2 channels expressed in CHO cells generated
voltage-dependent K+-selective currents characterized by a slow
time course of activation and deactivation, and a threshold for
current activation around −50 mV (Fig. 1B). Homomeric KV7.2
R6W and KV7.2 R6Q channels also generated functional volt-
age-dependent K+ currents that had maximal densities identical
to KV7.2 channels (Table 1), but required more depolarized
potentials to become activated; indeed, the threshold voltages
for current activation were −10 mV in KV7.2 R6W channels and
0 mV in KV7.2 R6Q channels (Fig. 1B). The half activation
potential (V1/2) was −23 mV in KV7.2 channels; this value was
right-shifted by 58 mV and 68 mV in R6W and R6Q mutant
channels, respectively (Fig. 1C and Table 1). For homomeric
KV7.2 R6Q channels, these results conﬁrm previous data (11).
K+ currents carried by homomeric KV7.2 channels displayed
double-exponential activation kinetics (1, 14), with a voltage-
dependent fast time constant (τf) and a slow time constant (τs)
showing little voltage sensitivity between −20 and +60 mV (15).
τf relative amplitude accounted for approximately 90% of the
total activation process. Compared with KV7.2 channels, currents
carried by KV7.2 R6W or KV7.2 R6Q homomeric channels
showed no appreciable difference in the weighted average of τf
and τs (Fig. 1D). By contrast, deactivation kinetics of KV7.2 R6W
and, more so, KV7.2 R6Q channels were faster than those
recorded from KV7.2 channels (Fig. 1D). At the end of a −20 mV
step, a signiﬁcant fraction of KV7.2 channels appeared to still be
in the open state; by contrast, more complete deactivation was
observed for KV7.2 R6W and KV7.2 R6Q channels, the latter
being fully closed at the end of the voltage step (Fig. 1E).
Functional and Pharmacological Properties of KV7.2 and/or KV7.3
Heteromeric Channels Incorporating Mutant KV7.2 R6W and R6Q
Subunits. To evaluate the possible functional changes caused by
KV7.2 R6W and KV7.2 R6Q mutant subunits in heteromeric
assembly with KV7.2 and/or KV7.3 subunits, CHO cells were
transfected with KV7.2+KV7.3 cDNAs at a 1:1 ratio to mimic the
genetic balance of normal individuals, and with KV7.2+KV7.2
R6W+KV7.3 or KV7.2+KV7.2 R6Q+KV7.3 (each at 0.5:0.5:1
ratio) to mimic the genetic balance of individuals who carried the
mutant KV7.2 alleles in heterozygosity.
Incorporation of KV7.3 subunits into KV7.2+KV7.3 hetero-
meric channels generated currents with larger size and a reduced
sensitivity to the pore blocker tetraethylammonium (TEA) than
KV7.2 homomers (Table 1) (1, 16). Compared with KV7.2+
KV7.3-transfected cells, cells transfected with KV7.2+KV7.2
R6W+KV7.3 or KV7.2+KV7.2 R6Q+KV7.3 cDNAs generated
K+ currents of identical size and TEA sensitivity, suggesting that
these mutations failed to interfere with heteromeric subunit as-
sembly (Table 1). By contrast, as in homomeric conﬁguration,
heteromeric channels carrying mutations at the R6 residue in
KV7.2 displayed a reduced voltage sensitivity (Table 1), with
a larger degree of functional impairment in the currents recor-
ded from KV7.2+KV7.2 R6Q+KV7.3- compared with KV7.2+
KV7.2 R6W+KV7.3-transfected cells; in fact, the V1/2 values were
right-shifted by approximately +9 mV and +16 mV in R6W- and
R6Q-expressing cells, respectively (Fig. 2B and Table 1). As-
suming similar transcription/translation efﬁciency of WT and
mutant cDNAs and random assembly of KV7.2 and KV7.3 sub-
units (17), the majority of channels formed in the described
heteromeric conﬁguration incorporated a single mutant subunit.
When comparing the functional changes observed in homomeric
channels (carrying four mutant subunits) with those in the de-
scribed heteromeric conﬁguration, the extent of decreased volt-
age sensitivity appears proportional to the number of mutant
subunits incorporated. This seems consistent with the results in
which heteromeric channels formed by KV7.2 R6W+KV7.3 or
KV7.2 R6Q+KV7.3 channels (mostly containing two mutant
subunits per channel) showed an intermediated phenotype, with
V1/2 shifts of +26 mV and +37 mV, respectively (Table 1).
Given that homomeric KV7.2 channels might contribute to
IKM diversity at some neuronal sites (18–20) and might be more
prevalent during early development (21), the effects of both R6
KV7.2 mutations were also studied in heteromeric conﬁguration
with only KV7.2 subunits (1:1 ratio). Under this experimental
condition, which generated a larger proportion of channels
Fig. 1. Functional properties of homomeric KV7.2,
KV7.2 R6W, and KV7.2 R6Q channels. (A) (Upper)
Topological representation of a Kv7.2 subunit. The
R213 (R6) residue is highlighted. (Lower) Sequence
alignment of the S4 segments of the indicated Kv
subunits (www.ebi.ac.uk/Tools/psa/). Residues are
colored according to the following scheme: ma-
genta, basic; blue, acid; red, nonpolar; and green,
polar. (B) Macroscopic currents from KV7.2, KV7.2
R6W, and KV7.2 R6Q channels, in response to the
indicated voltage protocols. Current scale, 100 pA;
time scale, 0.1 s. The arrows indicate the threshold
voltage for current activation. (C) Conductance/
voltage curves. Continuous lines are Boltzmann ﬁts
to the experimental data. (D) Time constants for
ionic current activation (weighed average of τf and
τs; ﬁlled symbols) and deactivation (empty symbols)
for the indicated channels (n = 4–9). (E) Normalized
and superimposed current traces from KV7.2, KV7.2
R6W, and KV7.2 R6Q channels. Current scale, 100 pA;
time scale, 100 ms.








containing two mutant subunits, the gating changes observed
were intermediate between homomeric (four mutant subunits) and
single heteromeric subunits (Table 1); also under this experimental
condition, R6W-containing channels displayedmilder gating changes
compared with R6Q-substituted channels (Fig. 2C).
The functional changes prompted on channel gating by both
KV7.2 mutations at position R6 are opposite to those caused by
retigabine, a prototypic opener of channel formed by neuronal
Kv7 subunits (13). In fact, both in native IKM and in heterologously
expressed neuronal homomeric or heteromeric KV7 channels,
retigabine causes a concentration-dependent shift in the hyper-
polarizing direction of the voltage dependence of the channel
activation process (Table 1), accompanied by a slower channel
deactivation and a variable degree of maximal current potentia-
tion. The effects of retigabine appeared to be unaffected by
incorporation of subunits carrying the R6 mutations: in fact, in
both KV7.2+KV7.2 R6W+KV7.3 and KV7.2+KV7.2 R6Q+KV7.3
heteromers, retigabine fully reversed mutation-induced gating
changes, thereby restoring voltage sensitivity to WT values (Fig. 3
and Table 1). In these experiments, retigabine was used at a con-
centration (1 μM) close to that achieved in human plasma during
conventional oral drug treatment (22), considering a maximum
concentration of 500 to 1,500 ng/mL and a plasma protein binding
of approximately 80% (13). Higher retigabine concentrations (10
μM) caused a larger hyperpolarizing shift in activation of hetero-
meric channels, the extent of which was similar in channels con-
taining WT or R6W/Q mutant subunits (Table 1).
Computational Modeling. To test the possible functional effects of
the described gating changes on intrinsic neuronal excitability,
a series of simulations were run after incorporation of the kinetic
(activation/deactivation) and steady-state parameters experi-
mentally derived from KV7.2+KV7.3, KV7.2+KV7.2 R6W+
KV7.3, or KV7.2+KV7.2 R6Q+KV7.3 heteromeric channels into
a model CA1 hippocampal neuron. The number of APs was
calculated from 500-ms-long simulations, as a function of so-
matic current injections and peak IKM conductances. Typical
voltage responses and expanded sweep displays of the activated
conductances from control or mutant model cells during a 0.65-
nA somatic current injection and 120 pS/μm2 for IKM are shown
in Fig. 4 A and B, respectively. When AP number was studied
across a wide range of injected current (between 0.3 and 0.7 nA),
it was found that, whereas R6Q mutant cells responded with
a much higher number of spikes compared with control cells at
relatively low current injection values, R6W produced similar
effects only for larger input currents (Fig. 4C). It is noteworthy
that such a dramatic difference between R6Q and R6W mutants,
as well as between both mutants and WT channels, was observed
across a wide range of peak IKM conductances (between 0 and 170
pS/μm2; Fig. 4D). A strong mutation-induced increase in cell ex-
citability, with more dramatic effects prompted by R6Q compared
with R6W, was also observed when computer simulation were
run under the following experimental conditions: (i) when somatic
and axonal IKM incorporated the kinetic and steady-state param-
eters experimentally derived from KV7.2, Kv7.2/Kv7.2R6W, and
Kv7.2/Kv7.2R6Q heteromers (Fig. S1); (ii) when parameters from
Kv7.2/Kv7.3 heteromers were included to model the somatic
component of the IKM, whereas data for Kv7.2 homomers were
used to model the axonal IKM (Fig. S2); and (iii) when model
parameters were modiﬁed to generate bursting behavior upon IKM
blockade (Fig. S3).
Discussion
In humans, gene defects in KV7.2 cause neonatal epilepsies
characterized by a wide phenotypic heterogeneity. In fact, mutations
Fig. 2. Functional properties of heteromeric channels incorporating KV7.2
R6W or KV7.2 R6Q mutant subunits. (A) Macroscopic current traces from the
indicated heteromeric channels in response to the indicated voltage proto-
cols. Current scale, 200 pA; time scale, 0.1 s The arrows indicate the threshold
voltage for current activation. (B and C) Conductance/voltage curves for the
heteromeric channels formed by mutant subunits with KV7.2 and KV7.3 (B)
or with KV7.2 (C). Continuous lines are Boltzmann ﬁts to the experimental
data. The cDNA ratios were: 1:1 for KV7.2+KV7.3, KV7.2+KV7.2 R6W, and
KV7.2+KV7.2 R6Q, and 0.5:0.5:1 for KV7.2+KV7.2 R6W+KV7.3 and KV7.2+
KV7.2 R6Q+KV7.3. Current scale, 200 pA; time scale, 100 ms.
Table 1. Gating and pharmacological properties of KV7.2, KV7.2 R6W, and KV7.2 R6Q subunits in homomeric and heteromeric
conﬁguration with KV7.2 and/or KV7.3
Subunit n V1/2, mV k, fold mV/e Current density, pA/pF
3 mM TEA, %
of block Retigabine, ΔV
KV7.2 14 −22.9 ± 1.8 12.3 ± 0.6 25.9 ± 3.8 (0 mV) 89.0 ± 2 ND
KV7.2 R6W 12 35.4 ± 4.6*
,† 23.5 ± 2.1*,† 24.8 ± 4.5 (+60 mV) ND ND
KV7.2 R6Q 9 45.0 ± 1.9* 16.6 ± 1.1* 33.9 ± 8.1 (+60 mV) ND ND
KV7.2 R6E 12 101.2 ± 4.7*
,† 20.1 ± 1.8* 51.0 ± 11.0 (+120 mV) ND ND
KV7.2+KV7.2 R6W 6 −6.8 ± 3.1*,‡ 16.7 ± 1.7*,‡ 33.3 ± 13.1 (+40 mV) ND ND
KV7.2+KV7.2 R6Q 8 17.7 ± 3.3* 19.3 ± 1.0* 23.6 ± 3.8 (+40 mV) ND ND
KV7.2+KV7.3 17 −30.7 ± 1.4 11.7 ± 0.7 110.8 ± 20.7* (0 mV) 44.6 ± 5.1* −26.1 ± 1.4 (10 μM);−9.1 ± 2.4 (1 μM)
KV7.2 R6W+KV7.3 7 −4.4 ± 4.0§,{ 18.0 ± 1.2§ 92.1 ± 13.7* (+40 mV) 46.8 ± 6.4* −24.6 ± 0.8 (10 μM)
KV7.2 R6Q+KV7.3 14 6.7 ± 2.7
§ 20.2 ± 0.9§ 62.8 ± 9.3* (+40 mV) 45.6 ± 5.7* −31 ± 1.2 (10 μM)
KV7.2+KV7.2 R6W+KV7.3 15 −22.2 ± 2.0§,jj 15.2 ± 1.3§ 98.8 ± 12.5* (+40 mV) 45.8 ± 9.2* −12.7 ± 1.1(1 μM)
KV7.2+KV7.2 R6Q+KV7.3 12 −14.7 ± 2.6§ 14.6 ± 2.6§ 85.0 ± 17.9* (+4 0mV) 45.0 ± 5.4* −11.3 ± 1.3 (1 μM)





jjKV7.2+KV7.2 R6Q+KV7.3. ND, not
determined.
4388 | www.pnas.org/cgi/doi/10.1073/pnas.1216867110 Miceli et al.
in KV7.2 (5, 6) and, more rarely, KV7.3 (7) genes are well-known
causes of BFNS, a dominantly inherited neonatal epilepsy with
mostly favorable outcome. More recently, novel KV7.2 mutations
have been identiﬁed in children with severe forms of neonatal-
onset epileptic encephalopathies (8, 9), characterized by distinct
EEG and MRI features, and variable degrees of psychomotor
delays. Noteworthy, familial cases with more severe neurodevel-
opmental outcome have also been described in BFNS families
carrying Kv7.2 mutations (23–25).
Although the molecular basis for this striking phenotypic
variability is yet unknown, differences in the functional effects
caused by the speciﬁc amino acid substitutions have been sug-
gested as a plausible explanation (8). Therefore, in the present
study, we have investigated the molecular pathogenesis of
channel dysfunction caused by two mutations affecting the same
residue in the VSD of KV7.2, which are responsible for “KV7.2
epileptic encephalopathy” (R6Q) (8), or for BFNS (R6W) (12).
Macroscopic current analysis in transfected cells revealed that
both mutations, in homomeric or heteromeric conﬁguration with
KV7.2 and/or KV7.3, did not modify the maximal density of the
expressed currents, suggesting that channel trafﬁcking to the
plasma membrane was unaffected; instead, homomeric R6Q
mutant Kv1.1 channels were nonfunctional because of a matura-
tion deﬁcit (26). More importantly, channels carrying either
KV7.2 mutation at R6 showed a remarkable decrease in their
voltage sensitivity, with the R6Q mutation prompting more
dramatic effects compared with the R6W mutation. For both
mutations, the extent of gating impairment appeared pro-
portional to the number of mutant subunits incorporated, being
maximal in homomeric conﬁguration (four mutant subunits),
intermediate in channels mostly containing two mutant subunits
(in homomeric conﬁguration with KV7.2 subunits or in hetero-
meric conﬁguration with KV7.3 subunits), and smaller in het-
eromeric channels reproducing the genetic balance of affected
individuals (mostly containing a single mutant subunit). R6 is not
believed to contribute directly to gating charge movement,
a function mainly attributed to the ﬁrst four positively charged
residues in S4 (27); nevertheless, the reduced voltage sensitivity
of channels carrying R6 mutations appears as a consequence of
a decreased stability of the activated VSD conﬁguration, as
revealed by the faster and more complete deactivation, with no
appreciable difference in activation kinetics. Of note, a crucial
role for the R6 residue in stabilizing the activated conﬁguration
of the VSD and in the electromechanical coupling between VSD
repositioning and pore opening (28) has also been recently
revealed from gating current measurements in highly homolo-
gous KV7.4 channels (29).
A mild decrease of IKM function appears sufﬁcient to cause
BFNS, and haploinsufﬁciency seems to be the primary patho-
genetic mechanism for familial and sporadic cases of BFNS.
Such mild IKM impairment can be caused by mutations de-
creasing expression, intracellular trafﬁcking, polarized targeting,
or voltage sensitivity of Kv7.2 subunits (30). The R6 mutations
described here seem to be within this latter group. However, the
R6W mutation caused gating changes qualitatively and quanti-
tatively similar to those of previously described BFNS mutations
(14, 15, 31, 32). By contrast, the 16-mV positive shift in V1/2
observed upon incorporation of a single KV7.2 R6Q subunit in
heteromeric conﬁguration with KV7.2 and KV7.3 subunits to
recapitulate the genotype of the individual affected with KV7.2
encephalopathy (8), is the most dramatic among the functional
changes described in KV7.2 channelopathies (33). More dra-
matic effects of the R6Q mutation compared with the R6W
mutation were also observed in homomeric KV7.2 channels,
which have been suggested to contribute to IKM diversity at
Ranvier nodes in central and peripheral ﬁbers (18, 19) and,
possibly, presynaptic nerve terminals (20). Notably, in rat supe-
rior cervical ganglion neurons, Kv7.2 homomers appear to be
Fig. 3. Effect of retigabine on heteromeric KV7.2+KV7.3, KV7.2+KV7.2 R6W+
KV7.3, or KV7.2+KV7.2 R6Q+KV7.3 channels. (A) Current responses from the
indicated heteromeric channels to voltage ramps from −80 to 0 mV. C, con-
trol currents; RET, retigabine; W, washout. Current scale, 200 pA; time scale,
0.2 s. (B) Quantiﬁcation of the effects of RET on the indicated heteromeric
channels. Data are expressed as membrane potentials at which currents
reached 20% of their peak value for controls (black bars) and after RET ex-
posure (white bars). *P < 0.05 vs. corresponding controls; ns, not signiﬁcantly
different). Current scale, 200 pA; time scale, 200 ms.
Fig. 4. Modeling of the effects of the KV7.2 R213W
(R6W) and R213Q (R6Q) mutations on neuronal
excitability. Time courses of the somatic membrane
potential (A) and of the activated conductances (B;
only the ﬁrst 200 ms are shown) from CA1 neurons
expressing KV7.2+KV7.3 (black traces), KV7.2+KV7.2
R6W+KV7.3 (red traces), or KV7.2+KV7.2 R6Q+KV7.3
(blue traces) heteromeric channels, during a 500-ms
somatic current injection of 0.65 nA. (C) Input/out-
put (I/O) curves from cells expressing KV7.2+KV7.3
(black trace), KV7.2+KV7.2 R6W+KV7.3 (red trace), or
KV7.2+KV7.2 R6Q+KV7.3 (blue trace) heteromeric
channels. Number of APs (AP#) is expressed as a
function of the somatic current injected, using a 120
mS/μm2 peak IKM conductance. (D) Contour plots for
number of APs elicited by a 500-ms somatic current
injection from cells expressing KV7.2+KV7.3, KV7.2+
KV7.2 R6W+KV7.3, or KV7.2+KV7.2 R6Q+KV7.3 het-
eromeric channels as a function of current injection
and peak IKM conductance.








more prevalent during early development (21). Computational
results in a CA1 hippocampal model neuron revealed that, in
heteromeric conﬁguration with KV7.2 and KV7.3 subunits, in-
corporation of a single R6Q and, to a lesser extent, R6W subunit
markedly increased neuronal excitability. Similarly, Peters et al.
(34) showed that IKM-deﬁcient CA1 pyramidal cells displayed no
change in AP parameters, but showed increased excitability and
reduced spike-frequency adaptation after depolarizing current
injection. The results obtained, which showed that the KV7.2
encephalopathy-associated R6Q mutation prompted gating alter-
ations signiﬁcantly more pronounced than the BFNS-associated
R6W mutation, suggest that the extent of mutation-induced
functional impairment may be related to the clinical severity of the
disease, thus uncovering unique genotype–phenotype correlations
in KV7.2-linked channelopathies.
The observation that more dramatic functional changes were
found when R6 was substituted by a Q rather than by a W is
somehow surprising because, even though both amino acids lack
the positive charge, Q has a similar size to R, whereas W is
considerably bulkier. To achieve a better understanding of the
role of the R6 residue in channel gating, and to provide a plau-
sible structural hypothesis to explain the mutation-induced
functional changes, we built a homology model of the KV7.2
subunit (11) based on the crystal structure of the open conﬁgu-
ration of a Kv1.2/Kv2.1 chimeric channel (35) (Fig. 5A). In this
model, the activated VSD conﬁguration is stabilized by electro-
static interactions between S4 positively charged residues and
negative charges provided by the S1–S2 linker (32) and both S2
and S3 segments. In particular, R207 (R4) forms a salt bridge
with E130 in S2, an interaction stabilized by KV7 activators acting
as gating modiﬁers (36). On the contrary, R210 (R5) and R213
(R6) form ionized hydrogen bonds with an internal negative
amino acid cluster mostly provided by E140 in S2 and D172 in S3
(11, 15); in particular, R6 interacts with D172 in S3 (Fig. 5B).
The replacement of R6 with a Q (Fig. 5C) impeded such elec-
trostatic interactions, possibly destabilizing the VSD activated
conﬁguration; the fact that charge reversal at the R6 residue
(R6E; Fig. 5D) caused even more dramatic gating changes
compared with the R6Q charge neutralization (Table 1), is in
line with this hypothesis. By contrast, the introduction of a W
residue at R6, although also occluding the ionized hydrogen
bonds with the internal cluster of negative charges, may bring
about a π-stacking interaction with a neighbor F168 residue in S3
(Fig. 5E); such an interaction, although weaker than the ionized
hydrogen bond in KV7.2 subunits (37), may provide a certain
degree of VSD stabilization, thereby resulting in more subtle
functional effects. The fact that the functional differences be-
tween R6W and R6Q mutations were largely prevented upon
replacement of F168 with a nonaromatic leucine (Figs. S4–S6)
seems in line this hypothesis.
Although the present results do not cover the full spectrum of
possible mutation-induced channel dysfunction, and the severity
of the disease is likely inﬂuenced by additional, yet unknown
environmental and genetic risk factors, the present data provide
evidence for a major pathogenetic role of the described gating
changes in phenotypic expression of KV7.2 channelopathies.
Moreover, the presently described genotype–phenotype correla-
tions might have relevant impact on disease-management proce-
dures (i.e., for early genotyping) and on clinical course prediction.
In fact, neonatal seizures can be harmful to the developing brain
in experimental animals, and, possibly, in humans (38). In fact,
seizure severity appears as an indicator of subsequent neuro-
developmental outcome in children with hypoxic-ischemic en-
cephalopathy (39), and early recognition and treatment of seizures
can reduce brain injury in newborns with hypoxic-ischemic en-
cephalopathy (40).
Safer and more effective treatments for neonatal seizures are
strongly needed. First-line drugs (mostly phenobarbital and
phenytoin) are effective in fewer than 50% of cases (41), and
experimental data have raised concerns about the potential ad-
verse effects on brain development of anticonvulsant agents
currently used in neonates (42). Animal studies have previously
highlighted Kv7/IKM channels as targets for neonatal seizure
treatment (43). The present results indicate that the neuronal
Kv7/IKM opener retigabine, at clinically relevant concentrations
(13, 22), was able to restore normal function in channels carrying
KV7.2 subunits mutated at the R6 position, thereby setting the
preclinical basis for the potential use of Kv7/IKM openers as
a targeted therapy for neonatal seizures and to improve the
developmental outcome of neonates with KV7.2 encephalopathy.
Materials and Methods
Mutagenesis of KV7.2 cDNA and Heterologous Expression of WT and Mutant
KV7.2 cDNAs. Mutations were engineered in human KV7.2 cDNA cloned into
pcDNA3.1 by sequence overlap extension PCR with the Pfu DNA polymerase
as described previously (15). Channel subunits were expressed in CHO cells by
transient transfection using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. A plasmid encoding for EGFP (Clontech) was
used as transfection marker.
Whole-Cell Electrophysiology. Currents from CHO cells were recorded at room
temperature (20–22 °C) 1 to 2 d after transfection by using an Axopatch
200A (Molecular Devices) and the whole-cell conﬁguration of the patch-
clamp technique, with glass micropipettes of 3 to 5 MΩ resistance. The ex-
tracellular solution contained (in mM) 138 NaCl, 2 CaCl2, 5.4 KCl, 1 MgCl2, 10
glucose, and 10 Hepes, pH 7.4 adjusted with NaOH; the pipette (in-
tracellular) solution contained (in mM) 140 KCl, 2 MgCl2, 10 EGTA, 10 Hepes,
5 Mg-ATP, pH 7.3 to 7.4 adjusted with KOH. pCLAMP software (version
10.0.2) was used for data acquisition and analysis. Currents were corrected
ofﬂine for linear capacitance and leakage currents by using standard sub-
traction routines (Clampﬁt module of pClamp 10). No corrections were made
for liquid junction potentials.
To generate conductance–voltage curves, the cells were held at −80 mV,
then depolarized for 1.5 s from −80 mV to +20/+120 mV in 10-mV incre-
ments, followed by an isopotential pulse at 0 mV of 300 ms duration. Cur-
rent values at the beginning of the 0-mV pulse were measured, normalized,
expressed as a function of the preceding voltages, and ﬁtted to a Boltzmann
distribution of the form y =max/[1 + exp(V1/2 − V)/k] to obtain V1/2 and slope
factor k. Current traces were ﬁt to a single- or a double-exponential func-
tion; in the latter case, a single time constant representing the weighted
average of the slow and fast components was obtained by using the fol-
lowing equation: τ = (τf Af + τs As)/(Af + As).
In the experiments with TEA or retigabine (obtained from Valeant
Pharmaceuticals, Aliso Viejo, CA) currents were activated by 3-s voltage
ramps from −80 mV to 0 mV at 0.08-Hz frequency. TEA blockade was
expressed as the percentage of peak current inhibition produced by a 2-min
drug application; the effects of retigabine were expressed as the negative
Fig. 5. Homology models of KV7.2, KV7.2 R6W, KV7.2 R6Q, and KV7.2 R6E
subunits. (A) Homology model of activated conﬁguration of VSD of a single
KV7.2 subunit; only S2, S3, and S4 segments are shown for clarity. Charged
amino acids shown correspond to E130 (E1) and E140 (E2) in S2, D172 (D1) in
S3, and R198 (R1), R201 (R2), R207 (R4), R210 (R5), and R213 (R6) in S4. (B–E)
Higher magniﬁcation of the boxed region in A in a single KV7.2 (B), KV7.2 R6Q
(C), KV7.2 R6E (D), and KV7.2 R6W (E) subunit. To improve clarity, images in B–E
are shown after leftward rotation by 90° of the model shown in A.
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shift in the ramp voltage at which the currents reached 20% of their peak
value after 2-min drug application.
Computational Modeling. All simulations were carried out with the NEURON
program, version 7 (44), by using a previously described 3D model of a CA1
pyramidal neuron (45). Uniform passive properties were used over the
entire neuron, with Cm of 0.75 μF/cm2 and Rm of 37.3 kΩ/cm2 (τm = 28 ms).
Active somatic and dendritic properties included the following con-
ductances: sodium (INa), potassium delayed rectiﬁer (IDR), potassium tran-
sient (IA), potassium M (IKM), and nonselective, hyperpolarization-activated
(Ih); a low-threshold Ca
2+ and a Ca2+-dependent K+ conductance, as well as
a simple Ca2+ extrusion mechanism, were also included. INa, IDR, Ca
2+-, and
Ca2+-dependent K+ conductances were included at uniform density over
the somatodendritic region, and IA and Ih linearly increasing with distance
from the soma. IKM-generating Kv7 channels are mostly concentrated at the
axon initial segment (45, 46); therefore, the data shown in Fig. 4 were
obtained with a threefold larger density of IKM within the axonal over the
somatic compartment (45). IKM peak conductances (0–170 pS/μm2) refer to
somatic values. The IKM properties were implemented to ﬁt the steady-state
and kinetic values obtained in this work. The complete model and simu-
lation ﬁles are available for public download under the ModelDB section of
the Senselab database (http://senselab.med.yale.edu/modeldb/) (47).
Homology Modeling. Three-dimensional models of Kv7.2 subunits were
generated by homology modeling by using SWISS-MODEL (11, 48). A chi-
meric channel in which the voltage-sensor paddle (corresponding to the S3b–
S4 region) of Kv2.1 was transferred into the Kv1.2 subunit (35) was used as
template (PDB ID code 2R9RH). The model was optimized through all-atom
energy minimization process by using the GROMOS96 implementation of
Swiss-PDBViewer, and analyzed by using both the DeepView module of
Swiss-PDBViewer (version 4.0.1; http://spdbv.vital-it.ch/) and PyMOL (http://
www.pymol.org/).
Statistics. Data are expressed as mean ± SEM. Statistically signiﬁcant dif-
ferences were evaluated with the Student t test or with ANOVA followed by
the Student–Newman–Keuls test, with the threshold set at P < 0.05.
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